JP2014523884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523884A5 JP2014523884A5 JP2014517251A JP2014517251A JP2014523884A5 JP 2014523884 A5 JP2014523884 A5 JP 2014523884A5 JP 2014517251 A JP2014517251 A JP 2014517251A JP 2014517251 A JP2014517251 A JP 2014517251A JP 2014523884 A5 JP2014523884 A5 JP 2014523884A5
- Authority
- JP
- Japan
- Prior art keywords
- edc
- antibody
- targeting moiety
- composition
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008685 targeting Effects 0.000 claims description 38
- 239000003814 drug Substances 0.000 claims description 34
- 229940124597 therapeutic agent Drugs 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- -1 Sel-1 Proteins 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 claims description 6
- 102100032412 Basigin Human genes 0.000 claims description 6
- 102100032912 CD44 antigen Human genes 0.000 claims description 6
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 claims description 6
- 101000798441 Homo sapiens Basigin Proteins 0.000 claims description 6
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 6
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 claims description 6
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 6
- 101000760337 Homo sapiens Urokinase plasminogen activator surface receptor Proteins 0.000 claims description 6
- 102100025818 Major prion protein Human genes 0.000 claims description 6
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 6
- 102100024689 Urokinase plasminogen activator surface receptor Human genes 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 4
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 4
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims description 2
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 102100024210 CD166 antigen Human genes 0.000 claims description 2
- 101000975407 Caenorhabditis elegans Inositol 1,4,5-trisphosphate receptor itr-1 Proteins 0.000 claims description 2
- 101000975393 Drosophila melanogaster Inositol 1,4,5-trisphosphate receptor Proteins 0.000 claims description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 2
- 108091008794 FGF receptors Proteins 0.000 claims description 2
- 102000027484 GABAA receptors Human genes 0.000 claims description 2
- 108091008681 GABAA receptors Proteins 0.000 claims description 2
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 claims description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 2
- 101001139093 Homo sapiens Klotho Proteins 0.000 claims description 2
- 101000937642 Homo sapiens Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 claims description 2
- 101000590830 Homo sapiens Monocarboxylate transporter 1 Proteins 0.000 claims description 2
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 claims description 2
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 2
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims description 2
- 108010001127 Insulin Receptor Proteins 0.000 claims description 2
- 102100036721 Insulin receptor Human genes 0.000 claims description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 2
- 102100020686 Klotho Human genes 0.000 claims description 2
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims description 2
- 101710138751 Major prion protein Proteins 0.000 claims description 2
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 claims description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims description 2
- 101710096328 Phospholipase A2 Proteins 0.000 claims description 2
- 102100026918 Phospholipase A2 Human genes 0.000 claims description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 2
- 108010025832 RANK Ligand Proteins 0.000 claims description 2
- 102000014128 RANK Ligand Human genes 0.000 claims description 2
- 108091006232 SLC7A5 Proteins 0.000 claims description 2
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 claims description 2
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 108050003222 Transferrin receptor protein 1 Proteins 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000006907 apoptotic process Effects 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims description 2
- 230000002538 fungal effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 102000006495 integrins Human genes 0.000 claims description 2
- 108010044426 integrins Proteins 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 125000002345 steroid group Chemical group 0.000 claims description 2
- 229940126585 therapeutic drug Drugs 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161500756P | 2011-06-24 | 2011-06-24 | |
| US61/500,756 | 2011-06-24 | ||
| US201161507882P | 2011-07-14 | 2011-07-14 | |
| US61/507,882 | 2011-07-14 | ||
| US201161551287P | 2011-10-25 | 2011-10-25 | |
| US61/551,287 | 2011-10-25 | ||
| PCT/US2012/044029 WO2012178173A1 (en) | 2011-06-24 | 2012-06-25 | Extracellular targeted drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014523884A JP2014523884A (ja) | 2014-09-18 |
| JP2014523884A5 true JP2014523884A5 (OSRAM) | 2015-08-13 |
Family
ID=47423002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517251A Pending JP2014523884A (ja) | 2011-06-24 | 2012-06-25 | 細胞外標的化薬物複合体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140193436A1 (OSRAM) |
| EP (1) | EP2723393A4 (OSRAM) |
| JP (1) | JP2014523884A (OSRAM) |
| CN (2) | CN103732259A (OSRAM) |
| WO (1) | WO2012178173A1 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2639301T3 (es) | 2003-04-30 | 2017-10-26 | Universität Zürich | Procedimientos de tratamiento de cáncer usando una inmunotoxina |
| RU2016116549A (ru) | 2013-10-02 | 2017-11-09 | Вивентиа Био Инк. | Антитела против epcam и способы их применения |
| WO2015105995A2 (en) * | 2014-01-08 | 2015-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted therapy for small cell lung cancer |
| JP2017506640A (ja) * | 2014-02-14 | 2017-03-09 | セントローズ， エルエルシー | 細胞外標的化薬物共役体 |
| JP2017114763A (ja) * | 2014-03-26 | 2017-06-29 | 第一三共株式会社 | 抗ｃｄ９８抗体−薬物コンジュゲート |
| HK1249020A1 (zh) * | 2015-03-12 | 2018-10-26 | Viventia Bio Inc. | 用於治疗epcam阳性膀胱癌的治疗方法 |
| CN107580501A (zh) | 2015-03-12 | 2018-01-12 | 维文蒂亚生物公司 | 用于靶向epcam阳性膀胱癌的给药策略 |
| US20190008983A1 (en) | 2015-07-31 | 2019-01-10 | James R. Prudent | Extracellular drug conjugates targeting cd20 |
| CA3015054A1 (en) * | 2016-02-18 | 2017-08-24 | Kyoto University | Complex capable of inhibiting genetic function in exosome, and cancer proliferation and/or metastasis suppressor |
| KR101923624B1 (ko) * | 2016-07-28 | 2018-11-30 | 고려대학교 산학협력단 | 암세포 화학요법을 위한 agtr1 압타머-항암약물 복합체 |
| US20190263931A1 (en) * | 2018-01-05 | 2019-08-29 | Immunext Inc. | Anti-mct1 antibodies and uses thereof |
| MX2020009044A (es) * | 2018-03-02 | 2020-10-12 | Evonik Operations Gmbh | Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales. |
| WO2019183375A1 (en) * | 2018-03-22 | 2019-09-26 | Eureka Therapeutics, Inc. | Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof |
| SG11202009451VA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Antibody-evading virus vectors |
| CA3094465A1 (en) | 2018-04-03 | 2019-10-10 | Stridebio, Inc. | Virus vectors for targeting ophthalmic tissues |
| JP7406677B2 (ja) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | 抗体を回避するウイルスベクター |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| JP7576542B2 (ja) * | 2018-08-02 | 2024-10-31 | ダイン セラピューティクス，インコーポレーテッド | 筋標的化複合体およびそれらの使用 |
| SG11202100934PA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3897657A2 (en) * | 2018-12-20 | 2021-10-27 | Universität Basel | <sup2/>? <sub2/>?+? ?na/k <ns1:sup>+</ns1:sup>?atpase inhibitors for use in the prevention or treatment of metastasis |
| MX2021013913A (es) * | 2019-05-14 | 2022-03-17 | Univ Duke | Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa. |
| US20220243210A1 (en) * | 2019-05-17 | 2022-08-04 | Ionis Pharmaceuticals, Inc. | Angiotensin ii type 1 receptor targeted oligonucleotides and uses thereof |
| TW202128736A (zh) | 2019-10-17 | 2021-08-01 | 美商史崔德生物公司 | 用於治療ｃ型尼曼—匹克病之腺相關病毒載體 |
| CN116745409A (zh) | 2020-08-19 | 2023-09-12 | 萨雷普塔治疗公司 | 用于治疗雷特综合征的腺相关病毒载体 |
| CN114917329B (zh) * | 2021-02-11 | 2023-07-21 | 兰州大学第二医院 | 抗cd87抗体与抗pd1抗体联合治疗胃癌 |
| WO2022178754A1 (en) * | 2021-02-25 | 2022-09-01 | Shanghai Allygen Biologics Co., Ltd. | Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof |
| AU2022309028A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| KR20240070519A (ko) * | 2021-08-05 | 2024-05-21 | 사네진 바이오 유에스에이 인크. | 1'-알킬 개질된 리보스 유도체 및 사용 방법 |
| TWI842088B (zh) | 2021-09-14 | 2024-05-11 | 美商伊穆諾米塔博立森發展公司 | 人類單羧酸鹽轉運蛋白1抗體及其用途 |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| CN117430697A (zh) * | 2022-07-21 | 2024-01-23 | 佰舟生物科技(苏州)有限公司 | 抗mct1抗体及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1360489A1 (en) * | 2001-02-05 | 2003-11-12 | Graffinity Pharmaceuticals Aktiengesellschaft | Low affinity screening method |
| CN109045307A (zh) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| JP2009529522A (ja) * | 2006-03-10 | 2009-08-20 | ディアト | 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤 |
| US8865875B2 (en) * | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| US8007808B2 (en) * | 2008-04-04 | 2011-08-30 | The Board Of Trustees Of The Univeristy Of Illinois | Composition and method for facilitating the internalization of a therapeutic agent into a cell |
| WO2010036460A2 (en) * | 2008-09-29 | 2010-04-01 | Centocor Ortho Biotech Inc. | Anti-cd147 antibodies, methods, and uses |
| CA2809819A1 (en) * | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
| CA2775291A1 (en) * | 2009-09-24 | 2011-03-31 | Xbiotech, Inc. | Methods, compositions, and kits for reducing anti-antibody responses |
| EP2533810B1 (en) * | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
-
2012
- 2012-06-25 CN CN201280039499.6A patent/CN103732259A/zh active Pending
- 2012-06-25 WO PCT/US2012/044029 patent/WO2012178173A1/en not_active Ceased
- 2012-06-25 CN CN201610948368.XA patent/CN107080847A/zh active Pending
- 2012-06-25 US US14/128,429 patent/US20140193436A1/en not_active Abandoned
- 2012-06-25 JP JP2014517251A patent/JP2014523884A/ja active Pending
- 2012-06-25 EP EP12803197.8A patent/EP2723393A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523884A5 (OSRAM) | ||
| US12403180B2 (en) | Interleukin-18 variants and methods of use | |
| Wang et al. | Breakthrough of solid tumor treatment: CAR-NK immunotherapy | |
| Barquilla et al. | Eph receptors and ephrins: therapeutic opportunities | |
| Bowser et al. | The hypoxia-adenosine link during inflammation | |
| JP2016509582A5 (OSRAM) | ||
| JP7525999B2 (ja) | キャリアー－ｐｄ－ｌ１結合剤組成物及び癌を処置する為にそれを使用する方法 | |
| ES2555160B1 (es) | Aptámeros específicos de TLR-4 y usos de los mismos | |
| Xiao et al. | Click reaction-assisted peptide immune checkpoint blockade for solid tumor treatment | |
| JP2013127002A5 (OSRAM) | ||
| JP2009521206A5 (OSRAM) | ||
| JP2016509585A5 (OSRAM) | ||
| JP2016502515A5 (OSRAM) | ||
| Ma et al. | Multipathway regulation for targeted atherosclerosis therapy using anti-miR-33-loaded DNA origami | |
| JP2015514756A5 (OSRAM) | ||
| McGonigle et al. | Neuropilin-1 drives tumor-specific uptake of chlorotoxin | |
| Li et al. | Staphylococcal superantigens use LAMA2 as a coreceptor to activate T cells | |
| Gahr et al. | Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma-review of the underlying molecular mechanisms and first case report | |
| D’Accardo et al. | Cancer cell targeting by CAR-T cells: A matter of stemness | |
| Karizak et al. | Understanding the regulation of “Don’t Eat-Me” signals by inflammatory signaling pathways in the tumor microenvironment for more effective therapy | |
| Wang et al. | Docetaxel enhances CD3+ CD56+ cytokine-induced killer cells-mediated killing through inducing tumor cells phenotype modulation | |
| Hassibian et al. | Aptamers: Design, Theory, and Applications to Diagnosis and Therapy for Diseases | |
| CA3231445A1 (en) | B7-h3 targeting fusion proteins and methods of use thereof | |
| CN107223133A (zh) | 一种可溶的异质二聚t细胞受体及其制法和应用 | |
| Suda et al. | High-mobility-group box chromosomal protein 1 as a new target for modulating stress response |